ArticleCancer research2012
Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women.
Article in Cancer research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- HPV vaccination among seropositive, DNA negative cohorts: a systematic review & meta-analysis.Journal of gynecologic oncology · 2022Pooled it
- Worldwide incidence of cervical lesions: a systematic review.Epidemiology and infection · 2015Pooled it
- The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review.Gynecologic oncology · 2014Pooled it
- HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test.British journal of cancer · 2017Trial
- Impact of switching from a quadrivalent to a nonavalent HPV vaccine on HPV infections and cervical cancer in Colombia: a mathematical modelling study.Lancet regional health. Americas · 2026Article
- Impact of Single- Versus Multiple-Type HPV Infections on Cervical Cytological and Histological Abnormalities: The Dominant Oncogenic Potential of HPV16 Single-Type Infections.Diagnostics (Basel, Switzerland) · 2025Article
- Comparative Oncologic Outcomes in High-Risk Human Papillomavirus-Positive and -Negative Cervical Intraepithelial Neoplasia.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Article
- The Prevalence of Multi-Type Infections Among Human Papillomavirus Types in Korean Women.Pathogens (Basel, Switzerland) · 2025Article
- Estimating the Age of Disease-causal HPV Infection Based on the Natural History of CIN2+ Among Females in Canada.Open forum infectious diseases · 2025Article
- Oral HPV incidence and risk factors for acquisition.Oral oncology · 2025Observational
- Comparing In Vitro Virucidal Efficacy of Commercially Available Mouthwashes Against Native High-Risk Human Papillomavirus Types 16 and 18.Microorganisms · 2025Article
- Population-based age- and type-specific prevalence of human papillomavirus among non-vaccinated women aged 30 years and above in Germany.BMC infectious diseases · 2024Article
- Article
- Article
- A qualitative study of primary care clinician's approach to ending cervical cancer screening in older women in the United States.Preventive medicine reports · 2023Article
- Epidemiologic characteristics of high-risk HPV and the correlation between multiple infections and cervical lesions.BMC infectious diseases · 2023Article
- Cervical Health in Systemic Lupus Erythematosus.Women's health reports (New Rochelle, N.Y.) · 2023Article
- Prevalence of HPV and associated factors in a population of women living in southern Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022Article
- HPV-Related Cervical Cancer and Extracellular Vesicles.Diagnostics (Basel, Switzerland) · 2022Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Understanding the fraction of newly detected human papillomavirus (HPV) infections due to acquisition and reactivation has important implications on screening strategies and prevention of HPV-associated neoplasia. Information on sexual activity and cervical samples for HPV DNA detection using Roche Linear Array were collected semiannually for two years from 700 women ages 35 to 60 years. Incidence and potential fraction of HPV associated with new and lifetime sexual partnerships were estimated using Poisson regression. Cox frailty models were used to estimate hazard ratios (HR) for potential risk factors of incident HPV detection. Recent and lifetime numbers of sexual partners were both strongly associated with incident HPV detection. However, only 13% of incident detections were attributed to new sexual partners, whereas 72% were attributed to 5 or more lifetime sexual partners. Furthermore, 155 of 183 (85%) incident HPV detections occurred during periods of sexual abstinence or monogamy, and were strongly associated with cumulative lifetime sexual exposure [HR: 4.1, 95% confidence interval (CI): 2.0-8.4). This association increased with increasing age. These data challenge the paradigm that incident HPV detection is driven by current sexual behavior and new viral acquisition in older women. Our observation that most incident HPV infection was attributable to past, not current, sexual behavior at older ages supports a natural history model of viral latency and reactivation. As the more highly exposed baby-boomer generation of women with sexual debut after the sexual revolution transition to menopause, the implications of HPV reactivation at older ages on cervical cancer risk and screening recommendations should be carefully evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.